When COVID-19 shut down waiting rooms across the country, telehealth went from a niche convenience to the backbone of healthcare delivery almost overnight. Federal and state agencies dismantled decades of regulatory barriers in a matter of weeks, enabling a scale of virtual care that would have seemed unthinkable in early 2020.

The result was one of the most dramatic natural experiments in health policy history. Millions of patients and providers adapted to remote consultations, remote prescribing, and digital monitoring — and many discovered they preferred it. Utilization surged from roughly 1% of outpatient visits to over 40% at the pandemic's peak.

Now the emergency declarations have ended, but the policy questions they created have not. Lawmakers face an unusually complex design challenge: how to preserve the genuine access gains of telehealth while building guardrails against overuse, fraud, and clinical shortcomings that emergency-era rules never had to address. The answers will shape how healthcare is delivered for a generation.

The speed of telehealth deregulation during COVID-19 was extraordinary. The Centers for Medicare & Medicaid Services waived geographic restrictions that had previously limited telehealth to patients in rural areas. Originating-site requirements — rules dictating that patients had to be at a clinic or hospital to receive virtual care — were suspended. Providers could suddenly deliver services across state lines, and audio-only phone calls became reimbursable for the first time in Medicare's history.

These weren't carefully designed reforms. They were emergency patches applied under crisis conditions. The waivers came through a patchwork of executive orders, congressional actions like the CARES Act, and agency-level guidance documents. Each layer had its own expiration timeline, creating a regulatory environment that even experienced policy analysts struggled to map. Some flexibilities expired with the public health emergency in May 2023; others were extended by Congress through the end of 2024 and beyond on a provisional basis.

The scheduled sunset of these waivers creates a recurring policy cliff. Providers who restructured their practices around telehealth face uncertainty about whether key services will remain reimbursable next year. Patients who came to rely on virtual visits — particularly those managing chronic conditions or behavioral health needs — risk losing access if flexibilities lapse without permanent replacements.

What makes this especially challenging is that these temporary rules were never subjected to the usual cost-benefit analysis or public comment process. Policymakers must now decide which emergency-era changes deserve permanence, armed with limited formal evidence about their long-term fiscal and clinical implications. The clock, in many cases, is already running.

Takeaway

Emergency policy is optimized for speed, not sustainability. The real design work begins when the crisis ends and temporary fixes must be evaluated on their permanent merits.

The emerging research on telehealth effectiveness is promising in some domains and genuinely ambiguous in others. Behavioral health stands out as a clear success story. Multiple studies have found that video-based therapy and psychiatric consultations achieve outcomes comparable to in-person care, with significantly lower no-show rates. For patients with anxiety, depression, or substance use disorders, the reduced friction of a virtual visit appears to meaningfully improve engagement with treatment.

Primary care and chronic disease management present a more nuanced picture. Follow-up visits for stable conditions — medication adjustments for hypertension, diabetes check-ins, post-surgical recovery monitoring — translate well to telehealth. But initial diagnostic evaluations, conditions requiring physical examination, and complex multi-system complaints lose important clinical information in a virtual format. The question isn't whether telehealth works; it's for which services and which patients it works well enough.

Access equity adds another layer of complexity. Telehealth was celebrated for reaching underserved populations, and it did expand access for some — particularly those in rural areas with long travel times to specialists. But it simultaneously exposed a digital divide. Older adults, low-income patients, individuals with limited broadband access, and those with limited English proficiency all showed lower telehealth uptake. Audio-only visits partially bridged this gap, which is why the reimbursement status of phone-based consultations has become such a contested policy question.

Perhaps most importantly, the long-term data on utilization patterns is still thin. Early evidence suggests telehealth may be additive rather than substitutive in some cases — meaning patients use virtual visits on top of, not instead of, in-person care. If that pattern holds at scale, the cost implications for public payers are significant and complicate the narrative that telehealth is inherently cost-saving.

Takeaway

Effective policy distinguishes between services where telehealth is clearly appropriate, where it is clearly inadequate, and the large gray zone in between that requires ongoing evidence review rather than blanket rules.

Designing permanent telehealth policy means resolving several tensions simultaneously. Payment parity — reimbursing virtual visits at the same rate as in-person care — is the most politically visible. Providers argue that parity is essential to sustain telehealth infrastructure. Payers worry that equal reimbursement for a lower-cost modality inflates spending without proportional value. The middle ground likely involves differential rates calibrated to service complexity, but few stakeholders find compromise positions satisfying.

Fraud prevention is an equally serious design constraint. The emergency period saw documented increases in telehealth billing irregularities, including phantom visits, upcoding, and prescribing schemes facilitated by the relaxation of in-person requirements. Any permanent framework needs audit mechanisms and prescribing safeguards — particularly for controlled substances — without creating compliance burdens so heavy that they deter legitimate providers from offering virtual care.

Interstate licensure remains a structural barrier. The emergency-era waivers that allowed providers to practice across state lines expired, and no federal framework has replaced them. The Interstate Medical Licensure Compact covers some states but is far from universal. Without a scalable solution, telehealth's promise of connecting patients to distant specialists remains geographically constrained by a licensing system designed for brick-and-mortar medicine.

The most consequential design choice may be the least discussed: whether to build adaptive policy mechanisms rather than static rules. Given how rapidly both technology and evidence are evolving, rigid legislation risks being outdated before it takes effect. Some policy scholars advocate for frameworks that delegate clinical appropriateness determinations to expert panels with regular review cycles — a model closer to how drug formularies operate than how coverage policy is typically written.

Takeaway

The strongest telehealth policy won't be the one that gets every detail right on day one — it will be the one designed to learn and adjust as evidence accumulates.

Telehealth's pandemic-era expansion was a remarkable demonstration of what happens when regulatory barriers are removed under pressure. The harder question — which barriers served a purpose and which were simply obstacles — is what policymakers must now answer with far more deliberation than the crisis allowed.

The evidence so far suggests telehealth is neither the universal solution its enthusiasts claim nor the quality risk its skeptics fear. It is a powerful tool for specific contexts, and the policy challenge is matching the tool to the right clinical and demographic circumstances.

Getting this right matters beyond telehealth itself. How lawmakers handle this transition will signal whether the health system can integrate rapid innovation into durable, equitable policy — or whether emergency progress simply reverts to the regulatory status quo.